Anebulo Pharmaceuticals posts Q1 net loss

Anebulo Pharmaceuticals

13/11/2025 21:18

Overview

Anebulo fiscal Q1 net loss remains at $2.2 mln, consistent with last year

Operating expenses for fiscal Q1 decreased slightly to $2.3 mln

Company advances selonabant for pediatric cannabis toxicity with NIDA grant support

Outlook

Anebulo expects FDA collaboration for pediatric cannabis toxicity treatment

Result Drivers

NIDA GRANT SUPPORT - Co received $994,300 from NIDA grant to support selonabant study

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.05
Q1 Net Income
-$2.20 mln
Q1 Basic EPS
-$0.05
Q1 Operating Expenses
$2.30 mln


Analyst Coverage

The one available analyst rating on the shares is "hold"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Press Release: ID:nBwbS6VKa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)